Novel selective morpholine trace amine-associated receptor 1 partial agonists show promising preclinical effects for neuropsychiatric disorders and are well tolerated in healthy volunteers

Journal:
Molecular Psychiatry
Published:
DOI:
10.1038/s41380-026-03465-y
Affiliations:
3
Authors:
16
Go to article
Institutions Authors Share
F. Hoffmann-La Roche Ltd., Switzerland
16.000000
16.000000
 1.00
Interested in Pharmacology and Pharmaceutical Sciences?